The pivotal Phase 3 obesity trial (NCT06939296) enrolled 840 adults and achieved ~12% mean weight loss at 52 weeks with VCT220 120 mg and 160 mg, with mainly mild-to-moderate GI events and no hepatic safety signal
Who manufactured it, and under what quality system
"We are working with our legal team to hopefully reach out to them and cease and desist and have these products taken down," Wiebe said
However, current academic and practical discussions often emphasise management perspectives and technical expertise within a political context shaped by historical and contemporary practices
GLOW is best understood as a regenerative support protocol , not a painkiller and not a performance drug
Another important issue was that only people with mild to moderate symptom severity were included in the study, as participants had to be able to travel for their scan